Research on the Mechanism Affecting Progression of Bronchiectasis Based on Omics Method

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test, Drug
Study Type: Observational
SUMMARY

Bronchiectasis is a chronic inflammatory respiratory disease defined as the irreversible dilatation of one or more bronchi and is associated with chronic and frequently purulent expectoration, multiple exacerbations and progressive dyspnea. Bronchiectasis has a large heterogeneity. Different patients with bronchiectasis may have different etiology, clinical manifestations, and imaging features. Previous studies showed that there are significant relationship between the airway microbiome and the severity of the disease. For example, patient with airway Pseudomonas aeruginosa colonization has heavier symptoms, heavier severity, poorer quality of life, more acute exacerbations, and worse prognosis. A large number of studies have reported that long-term treatment of low-dose macrolides such as azithromycin or clarithromycin has anti-inflammatory and immunomodulatory effects, which can improve the clinical symptoms and disease progression of various chronic airway diseases, such as diffuse panbronchiolitis, chronic obstructive pulmonary disease, bronchiectasis. Both the 2017 European Respiratory Society guidelines and the 2019 British Thoracic Society Guideline recommend macrolide drugs for the treatment of chronic Pseudomonas aeruginosa colonization bronchiectasis or frequent acute exacerbations bronchiectasis, but the specific mechanism is unknown.This study is based on omics methods (Microbiology and Metabolomics) to deeply explore the composition of airway and gut microbiota in patients with bronchiectasis, the factors affecting the colonization of Pseudomonas aeruginosa and the mechanism of macrolides in the treatment of bronchiectasis. This study collected clinical data of bronchiectasis (including demographic information, clinical characteristics, lung function, and lung imaging), spontaneous sputum, stool, and peripheral blood, and followed up these patients for 12 months. Microbiology,metabolomics and cytokine in sputum and stool are tested, and cytokines, inflammatory mediators and metabolites in peripheral blood are tested. Through the above methods,investigators further understand the mechanism affecting progression of bronchiectasis and some factors that lead to the colonization of Pseudomonas aeruginosa, as well as mechanisms of macrolides in the treatment of bronchiectasis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 18 years or older

• Bronchiectasis confirmed by high-resolution computed tomographic scan(HRCT)

• Chronic expectoration with ability to provide a sputum sample at the study visit

• Provision of written informed consent

Locations
Other Locations
China
Wuhan Union Hospital
RECRUITING
Wuhan
Contact Information
Primary
Xiaorong Wang
rong-100@163.com
18627195231
Backup
Yaya Zhou
749833758@qq.com
15972916036
Time Frame
Start Date: 2021-02-01
Estimated Completion Date: 2026-02-01
Participants
Target number of participants: 150
Treatments
Pseudomonas aeruginosa colonization group
Colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
Non-Pseudomonas aeruginosa colonization group
No colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
Before treatment with macrolides
Before treatment with macrolides in patients with bronchiectasis
After treatment with macrolides
After 6 months of treatment with macrolides for patients with bronchiectasis
Sponsors
Leads: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

This content was sourced from clinicaltrials.gov